Detail akcie Indaptus Thrp Rg online

Business Summary: Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Indaptus Therapeutics Inc revenues was not reported. Net loss increased 17% to $12.7M. Higher net loss reflects Research and development - Balancing val increase of 43% to $6M (expense), Other income, net decrease of 69% to $95K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$34.82 to -$21.08.